6 Minute Walk Test
Click the buttons provided below to view information contained in a specific part of this record:
|
Reference 2
|
| Reference Details |
|
Kierkegaard, M.; Tollbäck, A.; (2007) Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy; Neuromuscular Disorders; December Vol. 17; Iss. 11; pp 943-949
|
|
| Other Information |
|
The objective was to describe test–retest reliability and feasibility of the six minute walk test in adult subjects with myotonic dystrophy type 1.
|
|
|
|
|
Reference 3
|
| Reference Details |
|
Ledoux, I.; Decostre, V.; Canal, A.; Hogrel, J.Y.; (2009) M.P.3.09 Relation between total power estimated from 3D accelerometric data and distance covered during the six-minute walk test; Neuromuscular Disorders; September Vol. 19; Iss. 8; pp 603-604
|
|
| Other Information |
|
The aim of this study was to study the relation between total power estimated from 3D-accelerometric data and distance covered during six-minute walk test.
|
|
|
|
|
Reference 4
|
| Reference Details |
|
Escolar, D.M.; Wokke, J.H.J.; Pestronk, A.; Carter, G.T.; Jaffe, K.M.; Laforęt, P.; (2006) G.P.1 01 Clinical presentation and disease progression in late-onset Pompe disease; Neuromuscular Disorders;
October; Vol. 16; Iss. 9; p 654
|
|
| Other Information |
|
The objective of this study was to characterize the clinical presentation of individuals with late-onset Pompe disease for the purpose of identifying outcome measures for future clinical trials.
|
|
|
|
|
Reference 5
|
| Reference Details |
|
P. Laforet, P.R. Clemens, D. Corzo, D. Escolar, J. Florence, A. van der Ploeg, S. Lake, J. Mayhew, A. Pestronk, B. Rosenbloom, A. Skrinar, M. Wasserstein; (2008) T.O.4 Safety and efficacy results from a randomized, double-blind, placebo-controlled study of alglucosidase alfa for the treatment of Pompe disease in juveniles and adults; Neuromuscular Disorders; October; Vol. 18; Iss. 9; pp 832-833
|
|
|
|
|
Reference 6
|
| Reference Details |
|
J.M. Florence, A. van der Ploeg, P.R. Clemens, D.M. Escolar, P. Laforet, B. Rosenbloom, M. Wasserstein, A. Skrinar, A. Pestronk, J.E. Mayhew; (2008) T.P.1.01 Use of the 6min walk test as an endpoint in clinical trials for neuromuscular diseases; Neuromuscular Disorders; October; Vol. 18; Iss.; 9; pp 738-739
|
|
|
|
|
Reference 7
|
| Reference Details |
|
C.M. McDonald, E.K. Henricson, J.J. Han, A.R. Nicorici, R.T. Abresch, L.A. Atkinson, A.L. Reha, G.L. Elfring, L.L. Miller (2008) T.P.1.02 The 6min walk test (6MWT) as a clinical trial outcome measure in Duchenne/Becker Muscular Dystrophy (DMD/BMD); Neuromuscular Disorders; October Vol. 18; Iss. 9; p 739
|
|
|
|
|
Reference 8
|
| Reference Details |
|
C. McDonald, E. Henricson, R.T. Abresch, A. Nicorici, L. Atkinson, A. Reha, G.L. Elfring, L.L. Miller; (2009) M.P.3.03 6-minute walk test in Duchenne muscular dystrophy: Longitudinal observations;
Neuromuscular Disorders; September; Vol. 19; Iss.; 8; pp 601-602
|
|
|
|
